Maze Therapeutics reports Q2 2026 results, cites progress on kidney disease pipeline
Maze says enrollment continues in its Phase 2 HORIZON and CIPheR trials, with cash runway extended into 2029.
Maze Therapeutics reported second quarter 2026 financial results on August 11, 2026, alongside updates on its two lead clinical programs targeting kidney and metabolic diseases.
For MZE829, an oral APOL1 inhibitor being studied in APOL1-mediated kidney disease (AMKD), the company said in March 2026 it announced positive topline data from the Phase 2 HORIZON trial in patients with broad AMKD, marking the first clinical proof-of-concept data in this genetically-defined population and showing a reduction in proteinuria that the company described as clinically meaningful.1 Maze said enrollment in HORIZON continues, with updated data expected in late 2026 or early 2027 across three cohorts of 10 to 15 patients each: AMKD without diabetes, AMKD with diabetes, and AMKD with severe focal segmental glomerulosclerosis.1 Based on those topline results, Maze said it intends to start a pivotal trial in the first half of 2027, pending feedback from regulators.1
On the second program, MZE782, an SLC6A19 inhibitor for phenylketonuria (PKU) and chronic kidney disease (CKD), the company said it has initiated the Phase 2 CIPheR trial measuring plasma phenylalanine reduction in PKU patients, with enrollment ongoing and topline data expected in 2027.1 Maze also said it is preparing a separate Phase 2 proof-of-concept study of MZE782 in CKD patients, measuring proteinuria reduction, which it expects to begin during the first half of 2027.1
On finances, Maze reported cash, cash equivalents and marketable securities of $494.9 million as of June 30, 2026, up from $360.0 million at the end of 2025.1 The company said this balance is expected to fund operations into 2029 under its current business plan.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.